Pioglitazone and Losartan Provides Additional Renoprotection
Information source: Shanghai Jiao Tong University of Medicine
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 2 Diabetes; Diabetic Nephropathy
Intervention: pioglitazone (Drug); losartan (Drug)
Phase: N/A
Status: Completed
Sponsored by: Shanghai Jiao Tong University of Medicine Official(s) and/or principal investigator(s):
Hui M Jin, MD, Principal Investigator, Affiliation: Shanghai No.3 People's Hospital
Summary
Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are
currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or
in combination with insulin. angiotensin II receptor antagonist losartan reduced the levels of
proteinuria. Whether Combination therapy with pioglitazone and losartan provides additional
renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.
Clinical Details
Official title: Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment
Eligibility
Minimum age: 32 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Fasting plasma glucose (FPG) level of 3. 3-9. 0mmol/L
- 2h plasma glucose level of 7. 5-13 mmol/L
- serum creatinine values between 190 and 660umol/L
- Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours
urinary protein concentration is ＞150mg
- Informed consent
Exclusion Criteria:
- Type1 diabetes or nondiabetic renal disease
- abnormal liver function
- heart dysfunction
Locations and Contacts
Additional Information
Starting date: January 2005
Last updated: August 14, 2006
|
